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incidence and epidemiology
Follicular lymphomas (FLs) are the second most frequent
subtype of nodal lymphoid malignancies in Western Europe.
The annual incidence of this disease has rapidly increased
during recent decades and has risen from 2–3/100 000 during
the 1950s to 5/100 000 recently [1].
diagnosis and pathology/molecular
biology
Diagnosis should be based on a surgical specimen/excisional
lymph node biopsy. Core biopsies should only be carried
out in patients without easily accessible lymph nodes (e.g.
retroperitoneal bulk), keeping in mind the possible hetero-
geneity of FL grading can be difficult to appreciate on core
biopsies and re-biopsy may be required if the material is not
adequate. Fine needle aspirations are inappropriate for a reli-
able diagnosis.
The histological report should give the diagnosis according
to the World Health Organization (WHO) classification.
Grading of lymph node biopsies is carried out according to
the number of blasts/high-power field (Table 1). FL grade 3A
(with sheets of blasts) is considered an aggressive lymphoma
and treated as such [2], whereas grade 1, 2 and 3A should be
treated as indolent disease [3]. Review, especially of grade 3A
or 3B, by an expert haematopathologist is advised if the infil-
tration pattern is atypical (diffuse areas, even with small
cells).
staging and risk assessment
Since treatment largely depends on the stage of the disease, initial
staging should be thorough, particularly in the small proportion
of patients with early stages I and II (10%–15%) (Table 2). Initial
work-up should include a computed tomography (CT) scan of
the neck, thorax, abdomen and pelvis, and a bone marrow aspir-
ate and biopsy (Table 3). Positron emission tomography (PET)–
CT improves the accuracy of staging for nodal and extranodal
sites and thus should be recommended for routine staging in FL
[IV, C] [4]. This is particularly important to confirm localised
stage I/II before involved-field radiotherapy.
A complete blood count, routine blood chemistry including
lactate dehydrogenase (LDH), β2 microglobulin and uric acid as
well as screening tests for human immunodeficiency virus
(HIV), hepatitis B virus (HBV) and hepatitis C are required.
The staging is carried out according to the Ann Arbor classifica-
tion system (Table 2), with mention of bulky disease (>7 cm)
when appropriate.
For prognostic purposes, a ‘Follicular Lymphoma-specific
International Prognostic Index’ (FLIPI, Table 4) has been
established [I, A] [6]. A revised FLIPI 2 (incorporating β2
microglobulin, diameter of largest lymph node, bone marrow
involvement and haemoglobin level) has been suggested for
patients requiring treatment which may be more informative on
progression-free survival (PFS) [7].
Extended gene-expression profiling of tumour biopsy suggests
a more favourable clinical course in cases with infiltrating
T cells, in comparison with cases with non-specific macrophage
bystander cells [5]. Recently, a clinicogenetic risk score (m7-
FLIPI) has been proposed based on mutation status of seven
candidate genes (EZH2, ARID1A, MEF2B, EP300, FOXO1,
CREBBP and CARD11) [8]; however, none of the techniques are
yet established in clinical routine practice. In addition, several
recent immunohistochemistry studies have reported conflicting
data; hence, biological parameters are still investigational for
†Approved by the ESMO Guidelines Committee: August 2002, last update August 2016.
This publication supersedes the previously published version—Ann Oncol 2014; 25
(Suppl. 3): iii76–82.
*Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via L. Taddei 4,
CH-6962 Viganello-Lugano, Switzerland.
E-mail: clinicalguidelines@esmo.org
cl
in
ic
al
pr
ac
tic
e
gu
id
el
in
es
clinical practice guidelines Annals of Oncology 27 (Supplement 5): v83–v90, 2016doi:10.1093/annonc/mdw400
© The Author 2016. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
 by guest on N
ovem
ber 15, 2016
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
prognostic assessment and are not yet suitable for clinical deci-
sion-making [9]. If possible, additional biopsy material should
be stored fresh frozen to allow for the possible future application
of additional molecular analyses.
treatment
first line
stage I–II. In the small proportion of patients with limited
non-bulky stages I–II, radiotherapy (involved field, 24 Gy) is the
preferred treatment with a potentially curative potential, whereas
the 2 × 2 Gy schedule is inferior and is merely palliative [II, B]
[10]. In selected cases, watchful waiting or rituximab monotherapy
may be considered to avoid the side-effects of radiation (e.g.
cervical: sicca syndrome, hypothyroidism; abdominal: mucositis,
myeloablative suppression) [11, 12].
In stage I–II patients with large tumour burden, adverse clin-
ical or biological prognostic features or when local radiotherapy
is not applicable (e.g. lung, liver), systemic therapy as indicated
for advanced stages should be applied [IV, B] [12].
stage III–IV
induction: In the majority of patients with advanced stage III
and IV disease, no curative therapy is yet established. Since the
Table 2. Ann Arbor classification
Stage Area of involvement
I (IE) One lymph node region or extralymphatic site (IE)
II (IIE) Two or more lymph node regions or at least one lymph
node region plus a localised extralymphatic site(IIE) on
the same side of the diaphragm
III (IIIE, IIIS) Lymph node regions or lymphoid structures (e.g. thymus,
Waldeyer’s ring) on both sides of the diaphragm with
optional localised extranodal site (IIIE) or spleen (IIIS)
IV Diffuse or disseminated extralymphatic organ
involvement
A: no symptoms.
B: unexplained fever of >38°C, drenching night sweats; or loss of >10%
body weight within 6 months.
Table 4. ‘Follicular Lymphoma-specific International Prognostic
Index’ (FLIPI) risk factors
Parameter Definition of risk factors
FLIPI 1 FLIPI 2
Nodal sites >4 lymph node regions
(definition in [5])
Long diameter of largest
lymph node >6 cm
Age >60 years >60 years
Serum marker Elevated LDH Elevated β2
microglobulin
Stage Advanced (III–IV according
to Ann Arbor
classification)
Bone marrow
involvement
Haemoglobin <12 g/dl <12 g/dl
0–1 risk factors, low risk; 2 risk factors, intermediate risk; 3–5 risk
factors, high risk.
LDH, lactate dehydrogenase.
Table 1. Grading of follicular lymphoma (FL)
Grade Description
1 ≤5 blasts/high-power field
2 6–15 blasts/high-power field
3A >15 blasts/high-power field, centroblasts with intermingled
centrocytes
3B >15 blasts/high-power field, pure sheets of blasts
Table 3. Diagnostic work-up
History B symptoms
Physical examination Peripheral lymph nodes, liver, spleen
Laboratory work-up Blood and differential count
Optional: FACS on peripheral blood, PCR for
BCL2 rearrangement
LDH, uric acid
Electrophoresis (optional: immune fixation)
β2 microglobulin (FLIPI 2)
Serology Hepatitis B, C and HIV serology
Imaging CT neck, chest, abdomen, pelvis
Recommended: PET–CTa
Optional: abdominal ultrasound
Bone marrowb Histology
Cytology
Optional: FACS, PCR for BCL2 rearrangement
Toxicity Electrocardiogram, cardiac ultrasound (before
anthracyclines, ASCT)
Creatinine clearance
Reproductive counselling in young patients
aTo confirm localised disease or in the case of suspected transformation.
bIf clinically indicated.
FACS, fluorescence-activated cell sorting; PCR, polymerase chain
reaction; LDH, lactate dehydrogenase; FLIPI 2, Follicular Lymphoma
International Prognostic Index 2; HIV, human immunodeficiency virus;
CT, computed tomography; PET–CT, positron emission tomography–
computed tomography; ASCT, autologous stem cell transplantation.
Table 5. High tumour burden criteria in FL [Groupe d’Etude des
Lymphomes Folliculaires (GELF)
Parameter High tumour burden criteria
Lymph nodes Bulk (>7 cm) or 3 lymph nodes in distinct areas
>3 cm
Spleen Symptomatic splenic enlargement
(Potential)
complication
Organ compression by tumour, pleural or
peritoneal effusion
Serum markers Elevated LDH or elevated β2-microglobuline
Clinical presentation B symptoms (see Table 2)
LDH, lactate dehydrogenase.
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natural course of the disease is characterised by spontaneous
regressions in 10%–20% of cases and varies significantly from case
to case, therapy should be initiated only upon the occurrence of
symptoms, including B symptoms, haematopoietic impairment,
bulky disease, vital organ compression, ascites, pleural effusion or
rapid lymphoma progression (Table 5) [I, A].
In three randomised trials before the rituximab era, an early
initiation of therapy in asymptomatic patients did not result in
any improvement of disease-specific survival or overall survival
(OS) [13]. In a more recent study, early initiation of rituximab
resulted in improved PFS (80% versus 48%, P <0.001), but no
survival benefit has been determined so far [14], and the benefit
of rituximab maintenance in this setting appears doubtful [15].
Thus, the current therapeutic approach is based on clinical risk
factors, symptoms and patient perspective (Figure 1).
Four prospective first-line trials, two salvage trials and a sys-
tematic meta-analysis confirmed an improved overall response,
PFS and OS if rituximab was added to chemotherapy (Table 6)
[16–20]. If complete remission and long PFS is to be achieved,
rituximab in combination with chemotherapy such as CHOP
(cyclophosphamide, doxorubicin, vincristine and prednisone) or
bendamustine should be used [I, B] [17, 21]. CVP (cyclophos-
phamide, vincristine and prednisone) is not as effective as these
two regimens with respect to PFS but not OS [22]. Full courses of
purine analogue-based schemes [FC (fludarabine and cyclophos-
phamide) or FM (fludarabine and mitoxantrone)] are not recom-
mended due to higher haematological toxicities, but a brief
course of chemoimmunotherapy with full rituximab course is an
alternative in elderly patients, with good efficacy and low toxicity
[II, B] [22, 23]. If there is evidence (histological grade 3B or clin-
ical signs of transformation) of more aggressive lymphoma, an
anthracycline-based regimen [rituximab, cyclophosphamide,
Prognosis
Stage
FLIPI 1/2
Grade
Symptoms
Not mild
Life/organ threatening
Choose among
Asymptomatic cases:
Watch and wait
Patient priority
Longer survival
Long remission
Better quality of life
Evaluate
Mild symptoms:
Non-chemotherapy
treatment
Rituximab
Radioimmunotherapy
High tumour burden:
Chemoimmunotherapy
R-bendamustine
R-CHOP
R-CVP
Consider
rituximab maintenance
(or radioimmunotherapy)
Figure 1. Therapeutic algorithm. R-CHOP, rituximab, cyclophosphamide,
doxorubicin, vincristine and prednisolone; R-CVP, rituximab, cyclophos-
phamide, vincristine and prednisolone.
Table 6. Combined chemoimmunotherapy in FL (first line)
Study Total no. of patients Median follow-up Overall response Time to treatment failure
(months)
Overall survival
Marcus et al. [16] 159 53 months 81% 27 83% (4 years)
R-CVP (P < 0.0001) (P < 0.0001) (P = 0.029)
Hiddemann et al. [17] 223 58 months 96% NR 90% (2 years)
R-CHOP (P < 0.001) (P = 0.0493)
Herold et al. [18] 105 48 months 92% NR 87% (4 years)
R-MCP (P = 0.0009) (P < 0.0001) (P = 0.0096)
Bachy et al. [19] 175 99 months 81% 66 79% (8 years)
R-CHVP-IFN (P = 0.035) (P = 0.0004) (P = 0.076)
Rummel et al. [21] 139 34 months 93% NR 84% (4 years)
BR
Federico et al. [22] 34 months 95% (3 years)
R-CVP 178 88% 46% (3 years)
R-CHOP 178 93% 62% (3 years)
R-FM 178 91% 59% (3 years)
+ R maintenance
Vitolo et al. [23] 234 42 months 86% NR 89% (3 years)
4× R-FND + 4× R
± R maintenance
P, significance levels in comparison with chemotherapy only.
FL, follicular lymphoma; R-CVP, cyclophosphamide, vincristine and prednisolone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine,
prednisolone; R-MCP: mitoxantrone, chlorambucil, prednisone; R-CHVP-IFN, rituximab, cyclophosphamide, doxorubicin, etoposide, prednisone,
interferon; BR, bendamustine–rituximab; R-FM, rituximab, fludarabine and mitoxantrone; R-FND, cyclophosphamide, vincristine and prednisolone;
NR, not reached.
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doxorubicin, vincristine and prednisolone (R-CHOP)] should be
applied.
Antibody monotherapy (rituximab, radioimmunotherapy) or
chlorambucil plus rituximab remain alternatives for patients
with a low-risk profile or when conventional chemotherapy is
contraindicated [III, B] [24, 25].
In patients with positive hepatitis B serology including occult
carrier (HBS Ag negative and anti-core positive), prophylactic
antiviral medication and regular monitoring of HBV DNA are
strongly recommended [I, A] [26].
consolidation/maintenance
Rituximab maintenance for 2 years improves PFS (59% versus
43% after 6 years, P < 0.0001) [I, B] [27], whereas a shorter
maintenance period results in inferior benefit [28].
Radioimmunotherapy consolidation also prolongs PFS after
chemotherapy, but its benefit seems to be inferior in comparison
with rituximab maintenance for 2 years [II, B] [29, 30].
Myeloablative consolidation followed by autologous stem cell
transplantation (ASCT) prolongs PFS after chemotherapy, but
its benefit after a rituximab-containing induction is minor and no
OS has been observed [31]. Therefore, such an approach is not
recommended in first-line therapy of responding patients [I, D].
relapsed disease
At relapse, it is strongly recommended to obtain a new biopsy in
order to exclude transformation into an aggressive lymphoma.
It may be useful to target the biopsy based on PET scanning.
As at first presentation, observation is an accepted approach
in asymptomatic patients with low tumour burden.
Selection of salvage treatment depends on efficacy of prior
regimens. In early relapses (<12–24 months), a non-cross-resistant
scheme should be preferred (e.g. bendamustine after CHOP or vice
versa). Other options, including fludarabine-based, platinum salts-
based or alkylating agents-based regimens, could also be useful.
Rituximab should be added if the previous antibody-containing
scheme achieved >6- to 12-month duration of remission [IV, B].
On the other hand, obinutuzumab has recently received a positive
recommendation for approval by the European Medicines Agency
for rituximab-refractory cases based on an improved PFS in com-
parison with bendamustine only [I, B] [32].
In symptomatic cases with low tumour burden, rituximab
monotherapy may be applied.
Radioimmunotherapy (90yttrium–ibritumomab–tiuxetan) may
represent an effective therapeutic approach in elderly patients
with comorbidities not appropriate for chemotherapy [IV, B].
Rituximab maintenance for up to 2 years has a favourable
side-effect profile and, based on a systematic meta-analysis, sub-
stantially prolongs PFS and OS in relapsed disease, even after
antibody-containing induction in patients who have not
received antibody as first-line therapy [I, A] [33]. A second-line
maintenance treatment has not been investigated in the setting
of maintenance use in first line and probably should not be used
for those patients who had relapsed during their first mainten-
ance period [IV, D].
Table 7. Recommended follow-up after end of therapy
Examination Details Year 1–2 Year 3–5 Year >5
History B symptoms Every 3–4 months Twice annually Annually
Physical examination Particular: peripheral lymph nodes, liver, spleen Every 3–4 months Twice annually Annually
Laboratory work-up Blood and differential count Every 3–4 months Twice annually Annually
LDH Every 3–4 months Twice annually If progress suspected
Imaging Abdominal ultrasound Twice annually Every 12 months If progress suspected
CT neck, chest, abdomen, pelvis Optional: 6–12 months Optional: 12–24 months If progress suspected
LDH, lactate dehydrogenase; CT, computed tomography.
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Stage III/IV
Watch and wait
In selected cases,
consider rituximab
monotherapy
Watch and wait
Watch and wait
Radiotherapy
(involved field) 24 Gy
In selected cases,
consider watchful
waiting or rituximab
monotherapy
Watch and wait
Rituximab
monotherapy
Rituximab monotherapy
In selected cases,
palliative radiation
(e.g. 2 x 2 Gy)
In selected cases,
palliative radiation
(e.g. 2 x 2 Gy)
Watch and wait
Rituximab monotherapy
Chemoimmunotherapy
(long prior remission)
ldelalisib
(double refractory cases)
Chemoimmunotherapy
In selected cases,
rituximab monotherapy
Figure 2. Consensus-driven recommendations outside of clinical studies—
low tumour burden.
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High-dose chemotherapy with ASCT prolongs PFS and OS
and should be considered, especially in patients who experience
short-lived first remissions (<2–3 years) after rituximab-con-
taining regimens, which usually have a much worse long-term
outcome, but its general role in the rituximab era has to be rede-
fined [I, B] [34–37]. A subsequent rituximab maintenance may
achieve some improvement in PFS [II, B] [38].
In later relapses, monotherapy is an established option with
palliative intent [II, B]. The PI3K inhibitor idelalisib has been
registered in double-refractory FL, based on a phase II study
[39]. Recent analyses suggest an increased mortality risk as a
consequence of pulmonary morbidity (atypical pneumonias/
pneumonitis), so appropriate prophylaxis (cotrimoxazole/
acyclovir) is strongly recommended. Cytomegalovirus monitor-
ing may be also advised.
In selected younger patients with later relapses of high-risk
profile or relapse after ASCT, a potentially curative allogeneic
stem cell transplantation (preferably with dose-reduced condi-
tioning) may be considered, especially in patients with early
relapse and refractory disease [IV, B] [36].
innovative approaches
In recent years, new approaches, including lenalidomide–rituxi-
mab and additional inhibitors of the B-cell signalling pathway,
have proved active in phase II studies, but to date their benefit
High tumour burden
Stage Ill/IV
(<65 yearsa)
Stage Ill/IV
(>65 yearsa)
In selected cases, rituximab monotherapyFr
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n
Chemoimmunotherapy (e.g BR, R-CHOPb, R-CVP)
In selected cases,
rituximab-chlorambucil or rituximab monotherapy
CR/PR:
Recommend rituximab maintenance
(every 2 months, up to 2 years)
CR/PR:
Recommend rituximab maintenance
(every 2 months, up to 2 years)
• Chemoimmunotherapy (long prior remission)
+ rituximab maintenance (if not previously applied)
• In early relapses, discuss high-dose
consolidation with ASCTb
• Radioimmunotherapy or rituximab monotherapy
• ldelalisib (double refractory cases)
• In selected cases, discuss allogeneic transplantation
• Chemoimmunotherapy + rituximab
maintenance (every 3 months, up to 2 years)
• Alternatively, radioimmunotherapy
   • In early relapses, discuss high-dose
consolidation with ASCTb
Dependent on first-line regimen and remission duration
• Chemoimmunotherapy (e.g BR, R-CHOP, R-CVP)
+/- rituximab maintenance
(every 3 months, up to 2 years)
• Alternatively, radioimmunotherapy
Dependent on first-line regimen and remission duration
Dependent on prior regimens and remission duration
Chemoimmunotherapy (e.g. BRc, R-CHOPb, R-CVP) or brief
chemoimmunotherapy
• Chemoimmunotherapy (long prior remission)
+ rituximab maintenance (if not previously applied)
• Radioimmunotherapy or rituximab monotherapy
• ldelalisib (double refractory cases)
Dependent on prior regimens and remission duration
Figure 3. Consensus-driven recommendations outside of clinical studies—high tumour burden. R-CHOP, rituximab, cyclophosphamide, doxorubicin, vin-
cristine, prednisolone; R-CVP, cyclophosphamide, vincristine and prednisolone; BR, bendamustine–rituximab; CR, complete response; PR, partial response;
ASCT, autologous stem cell transplantation. aAccording to biological age; bespecially if transformation is suspected; c70–90 mg/m2, 4–6 cycles [42].
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has yet to be confirmed in randomised phase III studies. The
combination of bortezomib–rituximab has shown only a minor
benefit compared with antibody monotherapy [I, D].
response evaluation
Appropriate imaging evaluation should be carried out midterm
and after completion of chemotherapy. Patients with an inad-
equate response [less than partial response (PR)] should be eval-
uated for early salvage regimens. PR patients may convert to
complete response (CR) under rituximab maintenance.
PET–CT after completion of chemotherapy induction has
been recommended for prognostic reasons as persistent PET-
positivity (using appropriate Deauville scales) identifies a small
group (20%–25%) of patients with a worse prognosis [40], but
therapeutic consequences remain undefined [II, B].
Minimal residual disease (MRD) analysis by polymerase
chain reaction at the end of the treatment is an independent pre-
dictor of long-term outcome, but should not guide therapeutic
strategies outside of clinical studies.
personalisedmedicine
As various therapeutic approaches may achieve durable
responses in the vast majority of patients, the selection of
optimal treatment is mainly based on clinical risk factors, symp-
toms and patient perspective (Figure 1). PET- and MRD-based
tailored treatments are currently evaluated in studies but are not
yet routine clinical practice.
Paediatric FL is an FL variant originally described in children,
but occurs in adults as well. It is characterised by a localised
disease, the absence of bcl-2 aberrations, lack of t(14;18), grade
III and a high proliferation rate. It shows a much more indolent
course and should be managed with local therapy only, despite
displaying histologically more aggressive features [41].
follow-up and long-term implications and
survivorship
The following minimal recommendations are based on consen-
sus rather than on evidence (Table 7):
• After local radiotherapy: history and physical examination
every 6 months for 2 years, subsequently once a year if clinic-
ally indicated.
• After (during continuous) systemic treatment: history and phys-
ical examination every 3–4 months for 2 years, every 6 months
for 3 additional years, and subsequently once a year [V, D].
• Blood count and routine chemistry every 6 months for 2 years,
then only as needed for evaluation of suspicious symptoms.
• Evaluation of thyroid function in patients with irradiation of
the neck at 1, 2 and 5 years.
• Minimal adequate radiological or ultrasound examinations
every 6 months for 2 years and optionally annually up to 5
years. Regular CT scans are not mandatory outside of clinical
trials, especially if abdominal ultrasound is applicable. PET–
CT should be not used for surveillance.
• MRD screening may be carried out in clinical studies but
should not guide therapeutic strategies.
methodology
These clinical practice guidelines were developed in accordance
with the ESMO standard operating procedures for clinical prac-
tice guidelines development, http://www.esmo.org/Guidelines/
ESMO-Guidelines-Methodology. The relevant literature has
been selected by the expert authors. A summary of recom-
mended treatment strategies outside of clinical studies is pro-
vided in Figures 2 and 3, and a summary of recommendations is
provided in Table 8. Levels of evidence and grades of recom-
mendation have been applied using the system shown in
Table 9. Statements without grading were considered justified
Table 8. Summary of recommendations
In localised stages: radiation (24 Gy)
In advanced stages: treatment depends on clinical risk factors, symptoms
and patient perspective
Standard approach in asymptomatic advanced cases: watch and wait
In advanced symptomatic cases
Combined chemoimmunotherapy for long-term remissions
Recommend rituximab maintenance for consolidation
Relapse is frequently sensitive to conventional approaches
Autologous (and allogeneic) transplantation should be only discussed in
relapse
Monotherapy (antibodies, idelalisib) is appropriate, especially in later
relapses
Table 9. Levels of evidence and grades of recommendation
(adapted from the Infectious Diseases Society of America-United
States Public Health Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial
of good methodological quality (low potential for bias) or
meta-analyses of well-conducted randomised trials without
heterogeneity
II Small randomised trials or large randomised trials with a
suspicion of bias (lower methodological quality) or meta-
analyses of such trials or of trials with demonstrated
heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited
clinical benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh
the risk or the disadvantages (adverse events, costs,…),
optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
aBy permission of the Infectious Diseases Society of America [43].
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standard clinical practice by the experts and the ESMO faculty.
This manuscript has been subjected to an anonymous peer
review process.
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